JNJ
JOHNSON & JOHNSONCompany Information
- Company Name
- JOHNSON & JOHNSON
- CIK
- CIK0000200406
- Category
- Large accelerated filer
- Ticker: Exchange
- JNJ: NYSE
- Fiscal Year End
- January 03
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- JNJ
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-11-26
- Last sale
- 2026-06-11
- Shares purchased (TTM)
- 1,250
- Shares sold (TTM)
- 548,296
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 1,647,448,721
- Shares outstanding
- 2,408,700,000
- Ownership
- 68.40%
Earnings Market Reaction
- Filing date
- 2026-07-23
- Price on filing date
- —
- 1-month reaction
- Pending
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 20,422 | 21,688 | 19,709 | 18,231 | 18,577 | 38,474 | 24,105 | 19,980 | 24,878 | 25,473 | 21,859 | 19,728 | ||||||
| Marketable Securities Current | 336 | 363 | 393 | 331 | 303 | 307 | 417 | 317 | 597 | 745 | 1,068 | 3,783 | ||||||
| Accounts Receivable Net Current | 19,046 | 17,721 | 17,178 | 17,611 | 17,846 | 16,020 | 14,842 | 16,174 | 15,794 | 14,946 | 14,873 | 14,798 | ||||||
| Inventory Net | 15,144 | 14,583 | 14,191 | 14,146 | 13,412 | 12,659 | 12,444 | 12,603 | 12,169 | 11,383 | 11,181 | 11,198 | ||||||
| Prepaid Expense And Other Assets Current | 4,826 | 4,818 | 4,153 | 4,292 | 4,360 | 4,091 | 4,085 | 4,175 | 4,379 | 4,455 | 4,514 | 4,196 | ||||||
| Assets Current | 59,774 | 59,173 | 55,624 | 54,611 | 54,498 | 71,551 | 55,893 | 53,249 | 57,817 | 57,002 | 53,495 | 53,703 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Property Plant And Equipment Gross | 55,518 | 54,695 | - | 53,375 | 52,472 | 49,884 | - | 49,274 | 48,035 | 47,585 | - | 45,626 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | -31,936 | -31,425 | - | -31,037 | -30,523 | -29,013 | - | -28,795 | -28,287 | -27,953 | - | -26,805 | ||||||
| Property Plant And Equipment Net | 23,582 | 23,270 | 23,169 | 22,338 | 21,949 | 20,871 | 20,518 | 20,479 | 19,748 | 19,632 | 19,898 | 18,821 | ||||||
| Intangible Assets Net Excluding Goodwill | 48,229 | 49,061 | 50,403 | 48,737 | 49,835 | 36,755 | 37,618 | 39,490 | 39,725 | 34,286 | 34,175 | 35,021 | ||||||
| Goodwill | 48,479 | 48,558 | 48,772 | 48,048 | 48,117 | 44,468 | 44,200 | 44,799 | 44,250 | 36,616 | 36,558 | 36,124 | ||||||
| Deferred Income Tax Assets Net | 6,728 | 6,727 | 6,874 | 6,666 | 6,801 | 8,492 | 10,461 | 9,349 | 9,004 | 10,305 | 9,279 | 9,259 | ||||||
| Other Assets Noncurrent | 14,269 | 14,105 | 14,368 | 12,416 | 12,189 | 11,534 | 11,414 | 10,921 | 10,544 | 14,125 | 14,153 | 13,133 | ||||||
| Assets | 201,061 | 200,894 | 199,210 | 192,816 | 193,389 | 193,671 | 180,104 | 178,287 | 181,088 | 171,966 | 167,558 | 166,061 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Short Term Borrowings | 11,692 | 17,460 | 8,495 | 6,387 | 11,526 | 13,897 | 5,983 | 4,462 | 9,855 | 8,550 | 3,451 | 3,870 | ||||||
| Accounts Payable Current | 9,223 | 10,460 | 11,991 | 9,625 | 9,464 | 9,545 | 10,311 | 8,954 | 8,848 | 8,174 | 9,632 | 8,355 | ||||||
| Accrued Liabilities Current | 9,464 | 7,399 | 8,594 | 7,601 | 7,404 | 7,913 | 8,549 | 11,450 | 10,539 | 10,323 | 10,212 | 10,101 | ||||||
| Employee Related Liabilities Current | 3,475 | 2,911 | 4,534 | 3,972 | 3,298 | 2,551 | 4,126 | 3,620 | 2,843 | 2,178 | 3,993 | 3,337 | ||||||
| Accrued Income Taxes Current | 1,051 | 1,087 | 1,388 | 1,928 | 1,665 | 4,217 | 3,772 | 4,834 | 4,309 | 3,318 | 2,993 | 2,899 | ||||||
| Liabilities Current | 54,895 | 57,716 | 54,126 | 50,869 | 54,180 | 56,903 | 50,321 | 51,759 | 53,933 | 48,725 | 46,282 | 44,370 | ||||||
| Long Term Debt Noncurrent | 37,344 | 37,527 | 39,438 | 39,408 | 39,235 | 38,355 | 30,651 | 31,289 | 31,636 | 25,082 | 25,881 | 26,051 | ||||||
| Deferred Income Tax Liabilities Net | 6,608 | 7,011 | 6,791 | 5,988 | 3,799 | 2,428 | 2,448 | 2,952 | 2,635 | 3,172 | 3,193 | 2,623 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Employee Related Liabilities Current And Noncurrent | 6,657 | 6,760 | 6,957 | 6,930 | 7,021 | 7,046 | 7,255 | 6,852 | 6,919 | 7,019 | 7,149 | 5,687 | ||||||
| Accrued Income Taxes Noncurrent | 485 | 486 | 486 | 418 | 418 | 395 | 390 | 354 | 341 | 2,881 | 2,881 | 2,540 | ||||||
| Other Liabilities Noncurrent | 10,101 | 10,208 | 9,868 | 9,926 | 10,263 | 10,435 | 17,549 | 14,923 | 14,086 | 15,067 | 13,398 | 13,562 | ||||||
| Liabilities | 116,090 | 119,708 | 117,666 | 113,539 | 114,916 | 115,562 | 108,614 | 108,129 | 109,550 | 101,946 | 98,784 | 94,833 | ||||||
Stockholders Equity | ||||||||||||||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Preferred Stock Value | - | - | 0 | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Common Stock Value | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -13,951 | -14,831 | -14,930 | -15,237 | -14,305 | -11,740 | -11,741 | -12,522 | -11,253 | -10,768 | -12,527 | -8,780 | ||||||
| Retained Earnings Accumulated Deficit | 171,665 | 169,161 | 168,978 | 167,281 | 165,371 | 162,635 | 155,791 | 155,179 | 155,360 | 153,378 | 153,843 | 152,536 | ||||||
| Treasury Stock Value | - | - | 75,624 | - | - | - | 75,680 | - | - | - | 75,662 | - | ||||||
| Treasury Stock Common Value | 75,863 | 76,264 | - | 75,887 | 75,713 | 75,906 | - | 75,619 | 75,689 | 75,710 | - | 75,648 | ||||||
| Stockholders Equity | 84,971 | 81,186 | 81,544 | 79,277 | 78,473 | 78,109 | 71,490 | 70,158 | 71,538 | 70,020 | 68,774 | 71,228 | ||||||
| Liabilities And Stockholders Equity | 201,061 | 200,894 | 199,210 | 192,816 | 193,389 | 193,671 | 180,104 | 178,287 | 181,088 | 171,966 | 167,558 | 166,061 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 171 | 174 | 183 | 176 | 185 | 170 | 167 | 153 | 161 | 162 | 166 | 160 | ||||||
| Preferred Stock Shares Authorized | - | - | 2 | - | - | - | 2 | - | - | - | 2 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | ||||||
| Common Stock Shares Authorized | 4,320 | 4,320 | 4,320 | 4,320 | 4,320 | 4,320 | 4,320 | 4,320 | 4,320 | 4,320 | 4,320 | 4,320 | ||||||
| Common Stock Shares Issued | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | 3,120 | ||||||
| Treasury Stock Common Shares | 712 | 713 | 712 | 714 | 713 | 714 | 713 | 713 | 713 | 713 | 713 | 713 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialJOHNSON & JOHNSON (JNJ) — SEC Financial Statements & Analysis
JOHNSON & JOHNSON (JNJ) is a pharmaceutical preparations company, incorporated in NJ. JOHNSON & JOHNSON trades on NYSE as: JNJ. JOHNSON & JOHNSON (JNJ)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-23. Based on that filing, JOHNSON & JOHNSON carries a market cap of $611.41B, a P/E ratio of 29.06x, a P/B ratio of 7.20x, a P/S ratio of 6.24x, an enterprise value of $640.02B, and an EV/EBITDA multiple of 18.85x. On profitability, it posts a gross margin of 67.91%, an operating margin of 25.73%, a net margin of 21.48%, a Return on Equity (ROE) of 25.74%, a Return on Assets (ROA) of 10.67%, and a Return on Invested Capital (ROIC) of 19.19%. Per share, it reports EPS of $8.74, diluted EPS of $8.62, free cash flow per share of $9.24, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 8.06% year-over-year, net income growth of -7.17% year-over-year, and EPS growth of -7.21% year-over-year. On the balance sheet, it maintains a current ratio of 1.09x, a quick ratio of 0.73x, working capital of $4.88B, a debt-to-equity ratio of 1.37x, a debt ratio of 0.58, an interest coverage ratio of 25.90x, free cash flow of $22.24B (TTM), and net debt of $28.61B. Figures sourced from SEC EDGAR.
- Market Cap
- $611.41B
- P/E TTM
- 29.06x
- EPS TTM
- $8.74
- P/B TTM
- 7.20x
- ROE TTM
- 25.74%
- ROA TTM
- 10.67%
- Debt To Equity
- 1.37x
- Free Cash Flow TTM
- $22.24B
- Net Revenue TTM Growth 1Y
- 8.06%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is JOHNSON & JOHNSON in?
JOHNSON & JOHNSON (JNJ) operates in the Pharmaceutical Preparations industry.
What exchange does JNJ trade on?
JOHNSON & JOHNSON (JNJ) trades on the NYSE.
Where is JOHNSON & JOHNSON incorporated?
JOHNSON & JOHNSON is incorporated in NJ.
When was JOHNSON & JOHNSON (JNJ)'s most recent SEC filing?
JOHNSON & JOHNSON (JNJ)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-23.
What is JNJ's market cap?
JOHNSON & JOHNSON (JNJ) has a market capitalization of $611.41B as of 2026-06-30.
What is JNJ's P/E ratio?
JOHNSON & JOHNSON (JNJ)'s trailing twelve month P/E ratio is 29.06x as of 2026-06-30.
What is JNJ's EPS (earnings per share)?
JOHNSON & JOHNSON (JNJ)'s trailing twelve month EPS is $8.74 as of 2026-06-30.
What is JNJ's ROE (return on equity)?
JOHNSON & JOHNSON (JNJ)'s trailing twelve month Return on Equity (ROE) is 25.74% as of 2026-06-30.
What is JNJ's ROA (return on assets)?
JOHNSON & JOHNSON (JNJ)'s trailing twelve month Return on Assets (ROA) is 10.67% as of 2026-06-30.
What is JNJ's ROIC (return on invested capital)?
JOHNSON & JOHNSON (JNJ)'s trailing twelve month Return on Invested Capital (ROIC) is 19.19% as of 2026-06-30.
What is JNJ's EV/EBITDA?
JOHNSON & JOHNSON (JNJ)'s trailing twelve month EV/EBITDA is 18.85x as of 2026-06-30.